aceRNA Technology is a biotech startup dedicated to advancing targeted medicine through the innovative use of RNA Switch technology. This approach focuses on developing genetic therapies that specifically target diseased cells while minimizing impact on healthy cells, thereby reducing patient burden. The company aims to harness the unique properties of micro RNAs (miRNAs) to create therapies that can effectively regulate protein expression in response to the activity of these miRNAs. By utilizing RNA Switches, aceRNA Technology seeks to enhance the specificity and efficacy of gene therapies, addressing the challenges of side effects and low therapeutic applicability that often accompany traditional treatment methods.

The RNA Switch technology developed by aceRNA allows for the creation of both "OFF" and "ON" switches that can be activated or deactivated by specific intracellular miRNAs. This capability enables precise control over gene expression, making it particularly valuable in fields such as regenerative medicine and gene therapy. The company is focused on developing mRNA-based drugs that leverage this technology to fine-tune therapeutic gene expression, ultimately aiming to create "Smart mRNA" therapies. These innovative treatments promise to revolutionize the approach to disease management by minimizing unintended effects on non-target cells and enhancing the overall safety and effectiveness of therapies.

Japan

aceRNA Technologies Co., Ltd. is a biotech startup established in 2018 based on RNA design technology developed in synthetic RNA biology research by Prof. Hirohide Saito at Kyoto University. We are developing "smart gene therapy” (mRNA-based and virus-base) that enables control of therapeutic transgene expression in cell-type and -state specific manner. By that, we are committed to develop new therapeutic approach, such as in vivo cell programming.

aceRNA Technology

Company Details